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 The development of the ﬁrst authentic
BH3 mimetic, ABT-737, which heralded
the onset of translation of the above
ﬁndings into new anticancer medicines.
The recent FDA approval of a
BH3 mimetic, venetoclax, for
CLL, was a cancer breakthrough.
What do you see as the main
opportunities and challenges for
effective translation of these
therapies?
The life-death switch controlled by the
BCL-2 family operates downstream from
oncogenic mutations affecting numerous
signaling pathways. Furthermore, cancer
cells are more closely poised to apoptose
than are normal cells. Hence, BH3 mim-
etics should be effective for many cancer
cell types.
Although venetoclax has shown notable
activity as a single agent for CLL, optimal
therapy for most tumor types will most
likely require supplementation with
another anticancer agent, hopefully used
at a lower concentration than would be
normally be required for that drug.As with traditional cancer therapeutics,
the challenge is how to use BH3 mim-
etics without causing unacceptable
collateral damage. This requires deepen-
ing our understanding of the balance
of pro- and antiapoptotic proteins within
all normal cell types and tumors, so that we
can better predict which BH3 mimetic will
be the most effective in a particular tumor
type, and which normal cell types would be
most at risk with the regimen that is most
effective for the tumor.
Many tumors express high levels of the
BCL-2 prosurvival family member MCL-1,
which renders them resistant to both
navitoclax (speciﬁc for BCL-2, BCL-xL,
and BCL-w) and venetoclax (speciﬁc for
BCL-2). Thus, the recent announcement
of MCL-1-speciﬁc inhibitors is generating
much excitement. These new agents
should greatly expand the range of tumors
likely to be responsive to BH3 mimetictherapy and clinical trials are eagerly
awaited. Although safety concerns have
been raised by studies of mcl1–/–mice
showing vulnerability of cardiomyocytes,
liver cells, and neurons, a suitable thera-
peutic window may well be found because
mcl1+/–mice, which should mimic 50%
inhibition of the Mcl-1 protein, are normal
and healthy. Similar arguments can be
made for a Bcl-xL-speciﬁc BH3 mimetic,
which could prove useful for treating the
many solid tumors that express high levels
of Bcl-xL, provided safe regimens can be
implemented to avoid its toxicity for plate-
lets, which are Bcl-xL dependent.
A current challenge is to determine
whether BH3 mimetics can be used safely
in combination with various conventional
anticancer agents and, looking further
ahead, with each other. All in all, the pros-
pects for BH3 mimetic cancer therapy are
enormously exciting.
Where can we apply therapeutic
manipulation of cell death beyond
cancer?
One likely application is in immunosup-
pression. Gene ablation studies in mice
have taught us that apoptosis is vital for
shaping the immune repertoire and for
shutting down immune responses at the
appropriate time. Indeed, a failure of cell
death can readily provoke autoimmunity.
Thus, BH3 mimetics offer considerable
potential as more selective immunomod-
ulatory drugs than conventional agents.
It is thought that apoptosis may have
evolved largely to curtail infections by
pathogens. To counter this, many patho-
gens have developed genes that impair
apoptosis, such as the BCL2 homologs
in certain viruses and parasites. As the
pathogen sequences often differ radically
from those of the mammalian host, it
should be feasible to develop pathogen-
speciﬁc BH3 mimetics to limit the spread
of such infections.On the other side of the coin, degenerative
conditions arise from overly active celldeath. Therefore, there is considerable
interest in designing small molecules to
inhibit the activation of Bax and Bak, with
a view to testing their therapeutic potential
as agents to prevent certain degenerative
diseases.
What is the future of studying cell
death and survival and what are
the outstanding questions?
Determining how oligomerization of Bax
and Bak permeabilizes the outer mito-
chondrial membrane remains the out-
standing scientiﬁc question in apoptosis
research. Securing the answer has
seemed tantalizingly close for several
years, but further technological advances
in imaging and structural analysis of
membrane-bound proteins may yet be
required.
On the clinical side, the Holy Grail is to
learn how to use BH3 mimetic therapy,
either alone or in combination with other
drugs, to achieve durable cures, hopefully
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‘One general law, leading to the advance-
ment of all organic beings, namely, multi-
ply, vary, let the strongest live and the
weakest die’ (Charles Darwin in On the
Origin of Species). More than a century
and a half after Darwin made selection a
central biological concept, evolutionary
biology is at the vanguard of cancer
research. How is the Darwinian framework
shedding light on cancer incidence,
metastasis, or resistance and recurrence?
Among the leaders answering these ques-
tions is Mel Greaves, Founding Director of
the Centre for Evolution at The Institute of
Cancer Research (ICR) in London, UK. His
pioneering studies led to some of the most
fascinating discoveries on the aetiology of
childhood leukaemia. We asked Dr
Greaves to give us his view on the impli-
cations and beneﬁts of embracing an evo-
lutionary perspective towards cancer
biology and therapy.
You have always advocated that
cancer should be studied from an
evolutionary perspective. Why is
that so?
My answer is both pragmatic and philo-
sophical. Cancer, like other complex
problems in biomedicine and science gen-
erally, is more likely to be tackled success-
fully if we have a coherent and unifying
view of its fundamental nature.
In the 19th century, cancer was widely
regarded by surgeons and pathologists
as a ‘disease of civilization or stress’. Not
much of an advance on the ancient Greek
view that cancer was a manifestation of a
melancholic predisposition. In the 20th
century, inspired by Boveri, it was conﬁ-
dently concluded that cancer was ‘a
genetic disease’. This has now been super-
seded in the 21st century with the notion of
cancer as ‘a disease of the genome’.
There is of course an element of truth in
those latter descriptions, but in my view
they do not cut it. They fall short and lack
context. The problem here relates to how
scientists of different disciplines handle the
notion and meaning of ‘cause’. It is not540 Trends in Cancer, October 2016, Vol. 2, No. 10surprising that epidemiologists, cell and
molecular biologists, geneticists, and
oncologists, at least in the past, saw the
issue of cause somewhat differently with
respect to questions and answers.
To my mind, any fundamental explanation
of cancer as a disease has to accommo-
date three related challenges to be credi-
ble. One, what are the key ingredients of
cancer risk? Two, what drives (or
restrains) the emergence of a malignant
tumour? And, three, what is the mecha-
nistic basis of cancer cells’ resilience or
resistance to our best therapeutic tools?
An evolutionary perspective ﬁts the bill. It
provides a framework or context that can
make sense of the details. Dobzhansky
surely had it right in 1973 when he opined
that ‘Nothing in biology makes sense
except in the light of evolution.’ Although
I doubt if he had pathology and medicine
in mind as well.
In 1976, Peter Nowell, in his landmark
review in Science, highlighted that cancer
clones evolve or change over time, and
that this has relevance to treatment.
Embed that concept within a Darwinian
ecosystem context, and empower it with
genomic insights, and we have the
essence of cancer clone development,
as most practitioners of cancer research
and oncology now recognise. It's taken a
while.
But it is much more than that. I have
argued that by focusing on proximate
causal factors (important though they
may be from the perspective of preven-
tion) we miss a whole dimension of risk.
Cancer risk is inherent to the evolutionary
‘design’ of genome mutability, stem cells,
multicellularity, and our prior (beneﬁcial)
adaptations; for example with skin pig-
mentation and hormonal cycles. For me,
causal exposures only make sense in that
context.
And, ﬁnally, the resilience of advanced
cancer to therapeutic assault is perhapswhat you should expect of a semi-auton-
omous and robust cellular parasite. They
can call on survival tactics for which there
is a billion-year memory – playing by num-
bers with rare escapees fuelled by the
lottery of random mutation, exploiting sig-
nal network plasticity or hunkering down in
a dormant state. It's survival of the ﬁttest.
I started my scientiﬁc career in the 1960s
learning evolutionary biology from John
Maynard Smith and others, so I was
primed, and may be biased, from that
point on. But somehow the answer now
just seems so dammed obvious.
How are new technologies
enabling evolutionary studies?
There is no substitute for creative ideas in
science but, unquestionably, technologi-
cal innovations greatly fuel and accelerate
progress. They are enabling.
Evolutionary studies in cancer to date,
especially on cancer clone evolution,
have beneﬁted in particular from single-
cell analytical methods: monoclonal anti-
body-based immune-phenotyping, gene
expression signatures, genotypes and
lineage-tracking in vivo. These tools
have revealed remarkably complex and
dynamic phylogenetic architectures of
cancer cell clones and their variegated
genetics.
Tracking clonal evolution in real time via
sensitive serial screening of cell-free DNA
in plasma now offers the prospect of mon-
itoring the emergence of recurrent or
resistant clones, enabling prompt inter-
vention. This circumvents some of the
problems linked to the complex topogra-
phy of subclonal distribution in tissues and
the inherent selectivity or bias of biopsies.
Where do you feel cancer
evolutionary biology will have the
biggest impact?
The only thing that we can reliably predict
about the future is that it will happen. I
certainly hope that an evolutionary per-
spective will strongly endorse the
mutation rates and fast replication are win-importance and potential impact of pre-
vention and early intervention in cancer.
The epidemiological evidence linking most
common cancers to potentially avoidable
or modiﬁable lifestyle factors is strong.
Early tumours in most, although perhaps
not all cases, will be less resilient to chal-
lenge. A caveat is that we need to be
smarter at distinguishing or predicting
bad from benign players.
The biggest challenge is how best to
thwart the evolutionary resilience of can-
cers that present late in the clinic, for
example those of pancreas, lung, brain,
and ovary. Evolutionary principles and
methods are likely to be important, and
there is much that could be learned or
borrowed from other ﬁelds – antibiotic
resistance in bacteria and drug resistance
in malaria, tuberculosis, and HIV.
Some promising ideas are currently being
explored including therapeutic combina-
tions, coopting the versatility of recogni-
tion of the immune system into an arms
race in cancer. A new and exciting pros-
pect is evolutionary steering. Studies in
simpler microbial systems suggest that it
may be possible to design scheduling of
drug combinations to steer or push can-
cer clone evolution into a more benign cul-
de-sac.
What are the most exciting
questions in cancer evolution?
Once you embrace an evolutionary per-
spective, a host of exciting questions are
opened up. For me, one of the most inter-
esting is whether it is possible to both
predict in advance and then modify cancer
clone evolutionary trajectories.
I subscribe to the view that cells with self-
renewal, or stem cell-like potential, are the
cellular drivers of cancer evolutionary pro-
gression, metastasis, and recurrence or
relapse. The necessary caveat is that this
is not an inherent or stable state. I am
excited by the prospect of learning more
about how the self-renewal option oper-
ates and is regulated. Personalised,genome-guided therapeutics are a real if
challenging prospect, but isn’t there an
opportunity also for a more generic
approach tackling cancer via the essential
self-renewal bottleneck?
What other issues or challenges
remain unresolved in the drive to
understand and exploit the
evolutionary biology of cancer?
A whiff here of Rumsfeld's unknown
unknowns? We do have some important
known unknowns. We still remain ignorant
of some of the crucial biology of cancer
cells and are probably underestimating
complexity. I am somewhat wary of a very
gene-centric approach. It would be inter-
esting and potentially of practical value if
we had more insight into the ecosystem
pressures that select for improved ﬁtness
of cancer cells. But then to understand
cellular ﬁtness, we also need to have a
better grasp of how inherited gene variants
and acquired mutations operate collec-
tively or epistatically in a network providing
the phenotypic substrates for selection.
Despite being a biologist rather than a
clinician, I have always been a strong
advocate of ‘real’ or patient-based stud-
ies. Nevertheless, I suspect that further
validation and understanding of the ecol-
ogy of cancer will require better models of
the disease in vivo and in more realistic 3D
culture systems.
Are there other areas of medicine
where evolutionary thinking has
or can make a difference?
Certainly, and most obviously with antibi-
otic resistance, which has recently been
highlighted at the UN as an urgent, world-
wide problem. Evolutionary or Darwinian
medicine is a relatively new branch of bio-
medical sciences that seeks to apply evo-
lutionary principles to all areas of medicine
including chronic diseases of modern
societies – diabetes, obesity, and neuro-
degenerative conditions.
Perhaps the clearest example, other than
cancer, of evolutionary ideas being highlypertinent to medicine is with infectious
disease. Here we witness, not dissimilarly
to cancer, an arms race between rapidly-
evolving pathogenic species and the
immune surveillance system. Vaccination
can tip the balance in our favor, but highning cards for the bugs.
Overall, are you optimistic that
evolutionary studies of cancer will
be beneﬁcial?
One must be an optimist to survive and
thrive in science. But there are real and
tangible reasons for being optimistic that
an evolutionary perspective on cancer will
pay rich dividends; not least it's logical
coherence, technological underpinning,
and the superb cadre of young scientists




Preventing CancerWhen the Cancer Moonshot Blue Ribbon
Panel recommended early detection and
prevention as priority areas for research
Trends in Cancer, October 2016, Vol. 2, No. 10 541
